January 9, 2018

New risk group classification for prostate cancer

First system to integrate genomic biomarkers into routine clinical risk groups

Prostate cancer risk group classifications

Drs. Dan Spratt and Bob Dess have led a team from 19 institutions to develop a new risk group classification for prostate cancer that is the first system to integrate genomic biomarkers into routine clinical risk groups. This work was published in the Journal of Clinical Oncology, was an oral presentation at ASCO & ASTRO and featured in various news outlets and supplementary presentations such as the conversation with Alicia Morgan, MD in URO Today.

 

 

Daniel Spratt

Daniel Spratt, MD

Associate Professor
Associate Chair, Clinical Research
Chair, Genitourinary Clinical Research, Rogel Cancer Center
Director, Spine Oncology Program, Rogel Cancer Center
734-232-5244